Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617112 | 0.94 | ACHE (0.50) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL13617105 | 0.86 | ACHE (0.44) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7570219 | 0.86 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL26192235 | 0.85 | ACHE (0.55) | ACHETDP1 | |
| SCHEMBL14996237 | 0.84 | ACHE (0.64) | ACHEEPHX1 | |
| SCHEMBL27712904 | 0.84 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL1023071 | 0.84 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL12417367 | 0.84 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL7781306 | 0.84 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL5012046 | 0.84 | ACHE (0.49) | ACHEEPHX1TDP1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512106-B2 | Nucleoside analogue, preparation method and application | GENEMIND BIOSCIENCES COMPANY LIMITED (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20200283467-A1 | NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION | GENEMIND BIOSCIENCES COMPANY LIMITED (CN) | 2020-09-10 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283467-A1 | NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION | NUDT1, TYMP, PNP | ACHE 2769/4885EPHX1 1198/4885TDP1 324/4885 |
| US-11512106-B2 | Nucleoside analogue, preparation method and application | NUDT1, TYMP, PNP | ACHE 2769/4885EPHX1 1198/4885TDP1 324/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | ACHE 887/4885EPHX1 2453/4885TDP1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.